CDMO, AGC Biologics, has added two 5,000 L Thermo Scientific DynaDrive Single-Use Bioreactors (S.U.B.) at its new Yokohama, Japan facility, with GMP operations beginning in 2027.
The Yokohama facility is expected to help maximize operational and supply chain efficiencies across AGC Biologics’ global network by adding another site in the region.
AGC Biologics’ Yokohama facility will offer support from initial process development work for early-phase projects to late-phase and commercial production. It will support mammalian expression, cell therapy, and messenger RNA (mRNA) drug products.
“The new Yokohama site is designed to utilize single-use bioreactors to offer large-scale GMP manufacturing,” said Christoph Winterhalter, Chief Business Officer, AGC Biologics. “This location offers the capabilities to meet the commercial needs of customers in Japan and Asia, as well as global customers seeking capacity using the latest technology.”
